Clinical and Microbiologic Outcomes in Patients Receiving Treatment for Mycobacterium abscessus Pulmonary Disease

J Jarand, A Levin, L Zhang, G Huitt… - Clinical Infectious …, 2011 - academic.oup.com
Background. Mycobacterium abscessus can produce a chronic pulmonary infection for
which little is known regarding optimal treatment and long-term outcomes. Methods. We …

[HTML][HTML] Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study

…, A Dziwiecki, PD van Helden, S Siwendu, J Jarand… - The Lancet, 2010 - thelancet.com
Background Data from Kwazulu Natal, South Africa, suggest that almost all patients with
extensively drug-resistant (XDR) tuberculosis are HIV-positive, with a fatal outcome. Since, there …

High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers

MR O'Donnell, J Jarand, M Loveday… - Annals of internal …, 2010 - acpjournals.org
Background: Nosocomial transmission has been described in extensively drug-resistant
tuberculosis (XDR-TB) and HIV co-infected patients in South Africa. However, little is known …

Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and/or rifampin

J Jarand, JP Davis, RL Cowie, SK Field, DA Fisher - Chest, 2016 - Elsevier
Background Mycobacterium avium complex (MAC) lung disease requires prolonged treatment
with multiple antibiotics. Drug intolerances and interactions are common with the current …

New treatment options for multidrug-resistant tuberculosis

SK Field, D Fisher, JM Jarand… - … advances in respiratory …, 2012 - journals.sagepub.com
Despite the development of effective treatments, tuberculosis (TB) remains a major health
problem. TB continues to infect new victims and kills nearly 2 million people annually. The …

[HTML][HTML] The respiratory microbiome and nontuberculous mycobacteria: an emerging concern in human health

CS Thornton, M Mellett, J Jarand… - European …, 2021 - Eur Respiratory Soc
Nontuberculous mycobacteria (NTM) are diverse microbial species encompassing commensals
and pathogens with the ability to cause pulmonary disease in both immunocompetent …

Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey

…, W Hoefsloot, G Huitt, J Jarand… - Clinical Infectious …, 2021 - academic.oup.com
Adverse events are frequent in nontuberculous mycobacteria pulmonary disease treatment,
but evidence to support their management is scarce. An expert panel survey on …

Neurological complications of infliximab.

J Jarand, DW Zochodne, LO Martin, C Voll - The Journal of …, 2006 - jrheum.org
The use of anti-tumor necrosis factor-a (TNF-a) therapies has led to improved outcomes in
the treatment of rheumatoid arthritis (RA). However, the use of these new therapeutic agents …

Extensively drug‐resistant tuberculosis (XDR‐TB) among health care workers in South Africa

J Jarand, K Shean, M O'Donnell… - Tropical Medicine & …, 2010 - Wiley Online Library
Objective To determine the clinical profile and outcomes of health care workers (HCWs)
with extensively drug resistant tuberculosis (XDR‐TB) in the Eastern and Western Cape …

[HTML][HTML] Amiodaronoma: an unusual form of amiodarone-induced pulmonary toxicity

J Jarand, A Lee, R Leigh - CMAJ, 2007 - Can Med Assoc
Fig. 2: Chest CT scan showing an irregular hyperdense mass in the right upper lobe.
interstitial inflammation (Fig. 3). There was no evidence of malignant disease. Transmission …